8 research outputs found
Discovery of a Highly Tumor-Selective Organometallic Ruthenium(II)–Arene Complex
A rutheniumÂ(II)–arene complex
with a perfluoroalkyl-ligand
was found to display remarkable selectivity toward cancer cells. IC<sub>50</sub> values on several cancer cell lines are in the range of
25–45 μM, and no cytotoxic effect was observed on nontumorigenic
(HEK-293) cells at concentrations up to 500 μM (the maximum
concentration tested). Consequently, this complex was used as the
basis for the development of a number of related derivatives, which
were screened in cancerous and noncancerous cell lines. The lead compound
was then evaluated in vivo for antiangiogenic activity in the CAM
model and in a xenografted ovarian carcinoma tumor (A2780) grown on
the CAM. A 90% reduction in the tumor growth was observed
Multivariate Cox regression analysis with forward selection.
<p>HR = hazard ratio; CI = confidence interval.</p><p>Multivariate Cox regression analysis with forward selection.</p
Univariable analyses of standard clinical variables and galectin mRNA expression levels in relation to disease free survival in 87 patients with early stage NSCLC.
a)<p>Stage I vs. stage II, <sup>b)</sup>Squamous vs. others, <sup>c)</sup>Former smoker vs. others, <sup>d)</sup>Above vs. below median mRNA expression</p><p>Univariable analyses of standard clinical variables and galectin mRNA expression levels in relation to disease free survival in 87 patients with early stage NSCLC.</p
Galectin mRNA expression profile in tumor tissues obtained from early stage non-small cell lung cancer patients (n- = 87) (A).
<p>The inset shows the expression of the three galectin-9 splice variants. (B) Images of immunohistochemical staining of the galectins with detectable mRNA expression in NSCLC <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0107988#pone.0107988-Uhlen1" target="_blank">[27]</a>. (C) Western blot analysis of galectin-9 isoform expression in NSCLC tumor tissue from 5 different patients. Three bands at expected molecular weights of galectin-9FL, galectin-9Δ5 and galectin-9Δ5/6 were observed at varying intensities.</p
Images of immunohistochemical galectin-1 stainings (A: brown) and galectin-9 stainings (B: brown) of three representative tumors.
<p>Staining was observed in tumor cell compartment (T), stromal compartment (S) and in tumor endothelial cells (arrows). The inset on the left shows the isotype control staining. Scale bar = 50 micrometer. The bar graphs showing quantification of IHC scores for galectin-1 and galectin-9 in different tumor compartments.</p
Kaplan-Meier estimates of median OS and DFS in early stage NSCLC patients with galectin expression below or above the median level.
<p>HR = hazard ratio; CI = confidence interval.</p><p>Kaplan-Meier estimates of median OS and DFS in early stage NSCLC patients with galectin expression below or above the median level.</p
Kaplan-Meier plots of overall survival (OS) or disease free survival (DFS) in early stage NSCLC patients with low (Lo: below median) or high (Hi: above median) expression of galectin-1 (A), galectin-9FL (B) and galectin-9Δ5 (C).
<p>Kaplan-Meier plots of overall survival (OS) or disease free survival (DFS) in early stage NSCLC patients with low (Lo: below median) or high (Hi: above median) expression of galectin-1 (A), galectin-9FL (B) and galectin-9Δ5 (C).</p